Targeting STAT3 in cancer immunotherapy

S Zou, Q Tong, B Liu, W Huang, Y Tian, X Fu - Molecular cancer, 2020 - Springer
As a point of convergence for numerous oncogenic signaling pathways, signal transducer
and activator of transcription 3 (STAT3) is central in regulating the anti-tumor immune …

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond

M Platten, EAA Nollen, UF Röhrig, F Fallarino… - Nature reviews Drug …, 2019 - nature.com
Abstract l-Tryptophan (Trp) metabolism through the kynurenine pathway (KP) is involved in
the regulation of immunity, neuronal function and intestinal homeostasis. Imbalances in Trp …

The management of metastatic GIST: current standard and investigational therapeutics

CM Kelly, L Gutierrez Sainz, P Chi - Journal of Hematology & Oncology, 2021 - Springer
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the
gastrointestinal tract. The majority of GISTs harbor gain of function mutations in either KIT or …

Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial

M Toulmonde, N Penel, J Adam, C Chevreau… - JAMA …, 2018 - jamanetwork.com
Importance There is a strong rationale for treating sarcomas with immunotherapy. Objective
To assess the efficacy and safety of programmed cell death protein 1 (PD-1) targeting in …

Bacterial extracellular vesicles-based therapeutic strategies for bone and soft tissue tumors therapy

H Liu, H Zhang, Y Han, Y Hu, Z Geng, J Su - Theranostics, 2022 - pmc.ncbi.nlm.nih.gov
Bone and soft tissue tumors are complex mesenchymal neoplasms that seriously endanger
human health. Over the past decade, the relationship between microorganisms and human …

Immune checkpoint inhibitors: The linchpins of modern immunotherapy

BA Wilky - Immunological reviews, 2019 - Wiley Online Library
Immune checkpoint inhibitors (ICIs) have revolutionized our approach to cancer treatment in
the past decade. While monoclonal antibodies to CTLA‐4 and PD‐1/PD‐L1 have produced …

[HTML][HTML] Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: a systematic review and meta-analysis

M Saerens, N Brusselaers, S Rottey… - European Journal of …, 2021 - Elsevier
Abstract Background Soft-tissue sarcomas (STSs) are rare malignancies, accounting for
approximately 1% of adult cancer. Metastatic disease carries a poor prognosis, and various …

Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

B Li, H Chen, S Yang, F Chen, L Xu, Y Li, M Li, C Zhu… - Molecular cancer, 2023 - Springer
Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal
tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human …

[HTML][HTML] Src family kinases as therapeutic targets in advanced solid tumors: what we have learned so far

S Martellucci, L Clementi, S Sabetta, V Mattei, L Botta… - Cancers, 2020 - mdpi.com
Src is the prototypal member of Src Family tyrosine Kinases (SFKs), a large non-receptor
kinase class that controls multiple signaling pathways in animal cells. SFKs activation is …

Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors

A Hou, K Hou, Q Huang, Y Lei, W Chen - Frontiers in immunology, 2020 - frontiersin.org
Immune checkpoint inhibitors (ICIs) are starting to transform the treatment for patients with
advanced cancer. The extensive application of these antibodies for various cancer obtains …